UK: Of Mice And Patents — Kymab Beats Regeneron For Insufficiency

Last Updated: 23 February 2016
Article by Beatriz San Martín

This article was first published in Lexis®PSL IP & IT analysis on 11 February 2016.

What does this case tell us about insufficiency? Dr Beatriz San Martin, partner at Fieldfisher, draws out key points and lessons from Regeneron Pharmaceuticals Inc v Kymab.

Regeneron Pharmaceuticals Inc v Kymab Ltd and another [2016] EWHC 87 (Pat) [2016] EWHC 87 (Pat)

The Patents Court made rulings in a claim concerning transgenic mice that could be used as platforms for therapeutic antibody discovery. In dismissing the claim of Regeneron Pharmaceuticals, the court held that the defendants' counterclaim for insufficiency of the patent succeeded.

What is the commercial and legal background to this judgment?

The claimant, Regeneron, brought a claim for infringement of two of its European patents (UK) — EP(UK)1,360,287 (the 287 Patent) and EP(UK)2,264,163 (the 163 Patent) — with priority dates of 16 February 2001 (the priority date), which relate to transgenic mice that can be used as platforms for therapeutic antibody discovery. Kymab, the defendant, offered various strains of transgenic mice that were alleged, either per se or through the process by which they are produced, to infringe claims 5 and 6 of the 287 Patent and claim 1 of the 163 Patent (the Claims).

Kymab denied infringement and, as is usual in these cases, counter-claimed for revocation of the patents on the basis of insufficiency, 'cross anticipation', lack of novelty, obviousness and added matter. There was a second defendant, Novo Nordisk, although the claim against it was abandoned shortly before trial. For the purposes of this article, the reference to Kymab is to both defendants.

Claim 1 of the 287 Patent was also considered in detail as being relevant to the construction of claims 5 and 6 and issues of validity.

What were the legal aspects of the insufficiency attack?

Henry Carr J provided a summary of the law on both 'classical insufficiency' and 'excessive claim breadth' insufficiency before concluding that claim 1 of the 287 Patent was invalid for insufficiency on the basis that the whole of the subject matter of claim 1 was not capable of being performed at the priority date without undue burden and without invention. According to Henry Carr J: 'the task contemplated was unprecedented and could not have been achieved, if at all, without a great deal of creative thinking at the priority date.'

As Henry Carr J had concluded that claims 5 and 6 of the 287 Patent were of considerably wider scope than claim 1 of the 287 Patent, it followed that these two other claims were also invalid for insufficiency, as well as claim 1 of the 163 Patent.

What was said about product-by-process 'obtainable by' claims?

Claims 5 and 6 of the 287 Patent were product-by-process claims which used the phrase 'obtainable by'. The products in the case of claim 5 were a genetically modified eukaryotic cells or a mouse and, in the case of claim 6, a mouse embryonic stem cell containing a genetically modified immunoglobulin heavy chain variable region gene locus.

Henry Carr J gave a helpful summary of the principles derived from Hospira UK Ltd v Genentech Inc [2014] EWHC 3857 (Pat), in respect of 'obtainable claims':

  1. their purpose is to claim a product irrespective of how it was made but with a shared characteristic which results from using a given process;
  2. the claim has to specify the characteristics being referred to;
  3. 'obtainable by' claims present clarity problems and should only be permitted if there is no alternative way of defining the product in question; and
  4. for a product to be 'obtainable by' a process it must have every characteristic which is the inevitable consequence of that process.

What was the finding on infringement?

A feature of all of the claims of the 287 Patent was 'in situ replacement' of mouse variable region immunoglobulin (Ig) genes with human variable region Ig gene segments. The judge rejected Kymab's primary submission in support of non-infringement of all claims based on its construction of 'in situ replacement' and the submission that there was no infringement because the Ig sequence in Kymab's strains of mice had not been deleted. In Henry Carr J's judgment, 'in situ replacement' meant replacing 'in the position of' and was apt to describe a positional replacement and this included both replacement through deletion and by displacement/inactivation.

He also rejected Kymab's argument that it did not infringe because the inversion and displacement of the mouse V genes did not cause them to be substantially inactivated. Kymab had failed to point him to any evidence supporting this and Kymab's own publication and a witness under cross-examination indicated otherwise. Finally, he rejected the contention that the product was not 'obtainable by' the method of claim 1 because Kymab's mice carried more orthologous sequence (300kb) than could have been carried on a single bacterial artificial chromosome (BAC). There was no evidence that each insertion by Kymab was of an orthologous sequence greater than 300kb.

Overall, Henry Carr J held that all strains of the Kymab mouse (so-called Kymouse) were or would be generated from a product within the scope of claims 5 and 6 of the 287 Patent and that Kymouse strains having both modified IgH and IgK loci were mice within the scope of claim 1 of the 163 Patent.

What was the nature and outcome of the cross-anticipation attack involving priority?

Kymab claimed 'cross-anticipation' based on alleged loss of priority, ie that the patents were anticipated by matter that retained priority in the application for the other patent. This was, in Henry Carr J's own words, a complex argument which depended on:

  1. the proposition that the patents were insufficient at the priority date, and
  2. the results of a reference to the Enlarged Board of Appeal in T 557/13, which is not yet available

Henry Carr J did not consider it necessary to decide this issue, given that he had decided that the Claims were invalid for insufficiency. He did not think this argument advanced Kymab's case any further.

Are there any points for lawyers and their clients to take away?

Technical Primers

The judge admitted at para 6 that both the subject matter of the patents and the prior art were of great technical complexity. He found the agreed technical primer very helpful as an introduction to the technology and included parts of it in his judgment. He also encouraged lawyers to cooperate on this type of approach in other complex patent cases and congratulated the lawyers in this case for achieving an agreed document.

Submission on draft judgments

In the UK, draft judgments are circulated confidentially to legal counsel for suggested corrections of obvious errors. In this case, the judge received a further written submission on behalf of Regeneron alleging that there were certain material omissions in the draft judgment which should be considered before handing down the judgment.

While Henry Carr J made it clear that he did not criticise Regeneron's counsel for raising post-judgment submissions and he emphasised that lawyers should draw the court's attention to any material omissions in a judgment rather than saving up such points for the Court of Appeal, he also warned against this becoming a frequent occurrence. He noted that post-judgment submissions should be rarely necessary and that the temptation to raise just one more point in complex high value cases should be resisted. He reiterated that the primary purpose of circulating a draft judgment was to correct typographical or other obvious errors rather than to provide an opportunity to re-argue the case.

Criticism of experts

The judge noted that professor Francis Stewart appeared to have been unduly influenced by accounts from Kymab's legal team of the problems that Regeneron experienced in its research and development. This affected the weight that the judge attached to particular aspects of his evidence, although not his evidence in general. It was also noted that professor Howard's expert evidence was based on hindsight reasoning rather than his own involvement in the relevant field at the priority date and this was taken into account when considering the issue of inventive step.

This emphasises the need to choose experts carefully such that they have the relevant expertise at the priority date. It also highlights the care that should be taken to avoid providing personal opinions or anecdotes to experts when preparing expert reports.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Beatriz San Martín
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions